XY Therapeutics ApS
Private limited companyCVR 41120681CharlottenlundActive
XY Therapeutics ApS is a private limited company, based in Charlottenlund, active in research and experimental development on natural sciences and engineering, founded in 2020. Equity was negative at the end of 2025 (−DKK 9.5m). The company made a loss in both 2024 and 2025, most recently DKK 2.1m.
Key figures · financial year 2025
What has changed
calculated from recorded figures and datesFinancials: 2025 against 2024
- Gross profit rose 37% (2024 → 2025), to DKK 3.7m.
- The loss grew: from DKK 1.4m to DKK 2.1m (2024 → 2025).
Registrations, last 24 months
- 01/01/2025: Industry changed to Research and experimental development on natural sciences and engineering (721000)
Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.
Financial statements
Financial years 2021–2025 · amounts in DKK thousandEquity and net profit
| 2021 | 2022 | 2023 | 2024 | 2025 | Change | |
|---|---|---|---|---|---|---|
| Revenue | not stated | not stated | not stated | not stated | not stated | – |
| Gross profit | 153 | 627 | 362 | 2,681 | 3,677 | +37.2% |
| Operating profit (EBIT) | −2,874 | −2,419 | −632 | −1,032 | −1,976 | −91.5% |
| Profit before tax | −3,144 | −2,967 | −1,266 | −1,830 | −2,805 | −53.3% |
| Net profit | −2,531 | −2,384 | −1,152 | −1,370 | −2,096 | −53% |
| Total assets | 7,236 | 5,348 | 4,892 | 4,899 | 6,041 | +23.3% |
| Equity | −2,491 | −4,876 | −6,028 | −7,398 | −9,494 | −28.3% |
| Liabilities | 9,728 | 10,223 | 10,920 | 12,296 | 15,535 | +26.3% |
| Cash and cash equivalents | 6,616 | 4,126 | 4,195 | 4,324 | 4,850 | +12.2% |
| Average number of employees | 2 | 2 | 2 | 1 | 1 | 0% |
Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2021, 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.
Download the figures as CSV · free with an account, amounts in whole DKK
Signals from the financial statements
calculated from the 2025 figuresNegative equity
Equity was −DKK 9.5m at the end of 2025.
How is this calculated?
Equity in the latest annual report is below zero.
Loss for 5 years in a row
Net result has been negative in 2021–2025.
How is this calculated?
Net result is negative in the two or more latest annual reports in a row.
The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.
Annual reports
5 financial years| Financial year | Period | Published | Figures for | Documents |
|---|---|---|---|---|
| 2025 | 01/07/2024 – 30/06/2025 | 15/01/2026 | The company | PDF not statedXBRL |
| 2024 | 01/07/2023 – 30/06/2024 | 31/12/2024 | The company | PDFXBRL |
| 2023 | 01/07/2022 – 30/06/2023 | 02/01/2024 | The company | PDFXBRL |
| 2022 | 01/07/2021 – 30/06/2022 | 08/11/2022 | The company | PDFXBRL |
| 2021 | 28/01/2020 – 30/06/2021 | 09/12/2021 | The company | PDFXBRL |
The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.
Employees
monthly figures from CVRPosition in the industry
431 companies in the databaseComparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.
Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.
Compared with similar companies
size, age and company form| Group | Gross profit | Equity |
|---|---|---|
| Companies with fewer than 20 employees69,967 companies in the comparison | No. 18,687of 69,742 Better than 73% | No. 69,569of 69,964 Better than 1% |
| Same industry and fewer than 20 employees329 companies in the comparison | No. 60of 323 Better than 82% | No. 309of 329 Better than 6% |
| Companies that are between 5 and 14 years old33,688 companies in the comparison | No. 11,197of 33,588 Better than 67% | No. 33,343of 33,687 Better than 1% |
| All companies of type ApS66,508 companies in the comparison | No. 18,664of 66,379 Better than 72% | No. 66,102of 66,505 Better than 1% |
The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.
Compare with the industry
Research and experimental development on natural sciences and engineering- XY Therapeutics ApSDKK 3.7m
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- XY Therapeutics ApS−DKK 2.1m
- Carlsberg A/SDKK 7bn
- Zealand Pharma A/SDKK 6.5bn
- XY Therapeutics ApS−DKK 9.5m
- Carlsberg A/SDKK 30.7bn
- Zealand Pharma A/SDKK 14.8bn
- XY Therapeutics ApS2
- Carlsberg A/S107
- Zealand Pharma A/S569
Latest financial year per company. Choose up to three companies from the largest in the industry.
Owners and group
from the Public Ownership Register- Holding Fertility4U ApS100%
Management
1 active registrationsExecutive management
| Name | Role | Appointed |
|---|---|---|
| Martin Blomberg Jensen | Director | 28/01/2020 |
- Auditor
- Grant Thornton, Godkendt Revisionspartnerselskab
- Founders
- Holding Fertility4U ApS
Signing rule: Selskabet tegnes af én direktør
Address and production units
1 active production unitsRosenstandsvej 17A
2920 Charlottenlund
| Production unit | Address | Employees | P number |
|---|---|---|---|
| XY Therapeutics ApS | Rosenstandsvej 17A, 2920 Charlottenlund | 2 | 1025501949 |
Purpose
Selskabets formål er at udvikle løsninger til at forstå og forbedre reproduktion og relaterede aktiviteter
The purpose is quoted from the register in Danish.
Changes year by year
10 registered events20261 changeaccounts 1
- AccountsAnnual report for 2025 published
20251 changeindustry 1
- IndustryIndustry changed to Research and experimental development on natural sciences and engineering (721000)
20242 changesaccounts 2
- AccountsAnnual report for 2024 published
- AccountsAnnual report for 2023 published
20221 changeaccounts 1
- AccountsAnnual report for 2022 published
20212 changesaccounts 1 · name 1
- AccountsAnnual report for 2021 published
- NameName changed from Fertilitypro ApS to XY Therapeutics ApS
20203 changesfounded 1 · management 1 · ownership 1
- FoundedRegistered as Fertilitypro ApS
- ManagementMartin Blomberg Jensen appointed director
- OwnershipHolding Fertility4U ApS registered as owner (100%)
Related companies
Same industry in Gentofte
- Pharmaceutical Research Associates Denmark ApS50 employees
- Novo Nordisk Clinical Innovation Centre A/S32 employees
- Bioporto Diagnostics A/S28 employees
- NIVI Development A/S9 employees
- Bioporto A/S8 employees
- Protein Frontiers ApS4 employees
Largest in the industry
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Gubra A/SDKK 2.6bn
- Vestas Wind Systems A/SDKK 2.5bn
- Bang & Olufsen A/SDKK 1.4bn
- 3shape A/SDKK 1.3bn
Source and updates
The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026.